Product Code: GVR-1-68038-336-2
Pacemakers Market Growth & Trends:
The global pacemakers market size is anticipated to reach USD 5.94 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 3.4% from 2022 to 2030. This growth is owing to various factors such as technological advancements and the increasing prevalence of cardiovascular devices. Furthermore, the growing sedentary lifestyle coupled with the rising geriatric population is also anticipated to fuel the market growth during the projected period. During the COVID-19 pandemic, the market experienced a decline in revenues. This is owing to the postponement and cancellation of surgeries. According to the National Center for Biotechnology Information (NCBI), there was around a 73% reduction in de-novo pacemaker implantation during the initial months of the pandemic, which heavily impacted the market.
The increasing prevalence of cardiovascular diseases is a key growth driver for the market. As per the CDC in 2017, CVDs account for about 800,000 deaths in the U.S alone. Moreover, coronary heart disease accounts for the highest number of deaths, followed by stroke and heart failure. As per the British Heart Foundation Centre in 2018, nearly 7.4 million individuals are living with circulatory and heart diseases in the U.K. More than 43,000 individuals under 75 years of age die due to cardiac diseases every year in the U.K. To curb the rising prevalence of CVDs is government bodies and key market players are channelizing revenues to offer a potential treatment. This is anticipated by the influx of advanced products in this market space.
As per the CDC, 2020, more than 15% of U.S. adults are physically inactive that shows the prevalence of adult physical inactivity. Technological developments are quickly renovating the pacemaker market. Key players are focusing on expanding their current portfolio as in January 2020, BIOTRONIK launched an injectable cardiac monitor, BIOMONITOR III in Japan. It is intended to measure irregular heart rhythms with increased clarity. The injectable cardiac monitor also documents the unexplained syncope. Moreover, in November 2021, Abbott revealed the latest data for its Aveir leadless pacemaker for the treatment of patients with abnormal heart rhythms. The data demonstrated that the product if approved would provide various benefits during the treatment of slow heart rhythms.
Pacemakers Market Report Highlights:
- The market was valued at USD 4.38 billion in 2021 and is expected to witness a CAGR of 3.4% during the forecast period
- The MRI compatible pacemakers segment is expected to witness the highest CAGR from 2022 to 2030 owing to a higher patient preference rate as 75% of the patients with pacemakers are likely to get MRI during their lifetimes
- The atrial fibrillation segment held the largest revenue share in 2021 owing to the heightened prevalence of growing with age. As per the National Center for Biotechnology Information, 2020, nearly 6 to 12 million people globally are expected to suffer from atrial fibrillation in the US alone by 2050
- The biventricular pacemakers segment is expected to grow fast from 2022 to 2030. It is also known as Cardiac Resynchronization Therapy (CRT). An increase in the prevalence of heart failure is one of the major factors driving the demand for biventricular pacemakers
- Key companies are adopting new strategies to attain a competitive edge. Product development, collaborations, partnerships, mergers and acquisitions, and regional expansion are a few of them
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Estimates And Forecast Timeline
- 1.2. Research Methodology
- 1.3. Information procurement
- 1.3.1. Purchased Database
- 1.3.2. Gvr's Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
- 1.3.5. Details Of Primary Research
- 1.4. Information or Data Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity Flow Analysis(Model 1)
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
- 1.9.3. Objective 3
- 1.9.4. Objective 4
Chapter 2. Executive Summary
Chapter 3. Pacemaker Market Variables, Trends, and Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Penetration and Growth Prospect Mapping
- 3.3. Pacemaker Market Dynamics
- 3.4. Market Dynamics
- 3.4.1. Market Driver Analysis
- 3.4.1.1. Rising prevalence of cardiovascular diseases(CVD)
- 3.4.1.2. Favorable reimbursement policies
- 3.4.1.3. Technological advancements
- 3.4.2. Market Restraint Analysis
- 3.4.2.1. Stringent regulation and approvals
- 3.4.2.2. Product Recalls
- 3.4.3. Market Opportunity Analysis
- 3.4.4. Market Challenge Analysis
- 3.5. Pacemaker: Market Analysis Tools
- 3.5.1. Industry Analysis-Porter's
- 3.5.2. SWOT Analysis By Factors(Political & Legal, Economic, Social, And Technological)
- 3.6. Regulatory Framework
Chapter 4. Competitive & Vendor Landscape
- 4.1. Participation Categorization
- 4.2. Public Companies
- 4.2.1. Company Market Position Analysis
- 4.2.2. Pacemaker Market: Heat Map Analysis, 2021
- 4.3. Detailed List of Market Players
Chapter 5. Nebulizer Market: Covid-19 Impact Analysis
- 5.1. Current And Future Impact Analysis
- 5.1.1. Disease prevalence Analysis
- 5.2. Covid-19 Opportunity Analysis
- 5.2.1. Market entry strategies
Chapter 6. Pacemaker Market: Segment Analysis, By Product, 2017-2030(USD Million)
- 6.1. Product Market Share Analysis, 2021 & 2030
- 6.2. Global Pacemaker Market, by Product, 2017 to 2030
- 6.2.1. Implantable Pacemakers
- 6.2.1.1. Implantable pacemakers market, 2017-2030(USD Million)
- 6.2.1.2. Single Chamber
- 6.2.1.2.1. Single Chamber market, 2017-2030(USD Million)
- 6.2.1.3. Dual Chamber
- 6.2.1.3.1. Dual Chamber market, 2017-2030(USD Million)
- 6.2.1.4. Biventricular Chamber
- 6.2.1.4.1. Biventricular Chamber market, 2017-2030(USD Million)
- 6.2.2. External Pacemakers
- 6.2.2.1. External pacemakers market, 2017-2030(USD Million)
Chapter 7. Pacemaker Market: Segment Analysis, By Type, 2017-2030(USD Million)
- 7.1. Type Market Share Analysis, 2021 & 2030
- 7.2. Global Pacemaker Market, by Type, 2017 to 2030
- 7.2.1. MRI Compatible Pacemakers
- 7.2.1.1. MRI Compatible Pacemakers market, 2017-2030(USD Million)
- 7.2.2. Conventional Pacemakers
- 7.2.2.1. Conventional Pacemakers market, 2017-2030(USD Million)
Chapter 8. Pacemaker Market: Segment Analysis, By Application, 2017-2030(USD Million)
- 8.1. Application Market Share Analysis, 2021 & 2030
- 8.2. Global Pacemaker Market, by application, 2017 to 2030
- 8.2.1. Arrhythmias
- 8.2.1.1. Arrhythmias market, 2017-2030(USD Million)
- 8.2.1.2. Atrial Fibrillation
- 8.2.1.2.1. Atrial Fibrillation market, 2017-2030(USD Million)
- 8.2.1.3. Heart Block
- 8.2.1.3.1. Heart Block market, 2017-2030(USD Million)
- 8.2.1.4. Long QT Syndrome
- 8.2.1.4.1. Long QT Syndrome market, 2017-2030(USD Million)
- 8.2.2. Congestive Heart Failure
- 8.2.2.1. Congestive Heart Failure market, 2017-2030(USD Million)
- 8.2.3. Others
- 8.2.3.1. Others market, 2017-2030(USD Million)
Chapter 9. Pacemaker Market: Segment Analysis, By End Use, 2017-2030(USD Million)
- 9.1. End-use Market Share Analysis, 2021 & 2030
- 9.2. Global Pacemaker Market, By End Use, 2017 to 2030
- 9.2.1. Hospitals & Cardiac Centers
- 9.2.1.1. Hospitals & Cardiac Centers market, 2017-2030(USD Million)
- 9.2.2. Ambulatory Surgical Centers
- 9.2.2.1. Ambulatory Surgical Centers Market, 2017-2030(USD Million)
- 9.2.3. Others
- 9.2.3.1. Others market, 2017-2030(USD Million)
Chapter 10. Pacemaker Market: Regional Estimates & Trend Analysis, By Product, Type, Application, End Use 2017-2030(USD Million)
- 10.1. Regional Market Snapshot
- 10.2. North America
- 10.2.1. North America Market Estimates And Forecasts, By Country, 2017-2030(USD Million)
- 10.2.2. U.S.
- 10.2.2.1. U.S. pacemaker market, 2017-2030(USD Million)
- 10.2.3. Canada
- 10.2.3.1. Canada pacemaker market, 2017-2030(USD Million)
- 10.3. Europe
- 10.3.1. Europe Pacemaker Market, By Country, 2017-2030(USD Million)
- 10.3.2. U.K.
- 10.3.2.1. U.K. pacemaker market, 2017-2030(USD Million)
- 10.3.3. Germany
- 10.3.3.1. Germany pacemaker market, 2017-2030(USD Million)
- 10.3.4. France
- 10.3.4.1. France pacemaker market, 2017-2030(USD Million)
- 10.3.5. Italy
- 10.3.5.1. Italy pacemaker market, 2017-2030(USD Million)
- 10.3.6. Spain
- 10.3.6.1. Spain pacemaker market, 2017-2030(USD Million)
- 10.4. Asia Pacific
- 10.4.1. Asia Pacific Pacemaker Market, By Country, 2017-2030(USD Million)
- 10.4.2. Japan
- 10.4.2.1. Japan pacemaker market, 2017-2030(USD Million)
- 10.4.3. China
- 10.4.3.1. China pacemaker market, 2017-2030(USD Million)
- 10.4.4. India
- 10.4.4.1. India pacemaker market, 2017-2030(USD Million)
- 10.4.5. Australia
- 10.4.5.1. Australia pacemaker market, 2017-2030(USD Million)
- 10.5. Latin America
- 10.5.1. Latin America Pacemaker Market, By Country, 2017-2030(USD Million)
- 10.5.2. Brazil
- 10.5.2.1. Brazil pacemaker market, 2017-2030(USD Million)
- 10.5.3. Mexico
- 10.5.3.1. Mexico pacemaker market, 2017-2030(USD Million)
- 10.6. MEA
- 10.6.1. MEA Pacemaker Market, By Country 2017-2030(USD Million)
- 10.6.2. South Africa
- 10.6.2.1. South Africa pacemaker market, 2017-2030(USD Million)
- 10.6.3. Saudi Arabia
- 10.6.3.1. Saudi Arabia pacemaker market, 2017-2030(USD Million)
- 10.6.4. UAE
- 10.6.4.1. UAE pacemaker market, 2017-2030(USD Million)
Chapter 11. Company Profile
- 11.1. Osypka Medical GmbH
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Strategic Initiatives
- 11.2. Boston Scientific Corporation
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Strategic Initiatives
- 11.3. Zoll Medical Corporation
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Strategic Initiatives
- 11.4. Medtronic
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Strategic Initiatives
- 11.5. BIOTRONIK
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Strategic Initiatives
- 11.6. MicroPort Scientific Corporation
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Strategic Initiatives
- 11.7. Cook Medical
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Strategic Initiatives
- 11.8. MEDICO SpA
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.9. Pacetronix
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.10. Oscor Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking